Press releases - Ypsomed

mylife Loop offers new remote monitoring feature for parents

02/22/2023 - 7:00am Press Releases Ypsomed Group

Burgdorf – Parents and caregivers of children with diabetes can now follow their child's glucose and insulin data via the mylife CamAPS FX app on their own personal smartphone. The new "Companion remote monitoring" feature is fully integrated into the app. It gives parents and caregivers better control and peace of mind.

machine MD - Winner of the Ypsomed Innovation Award 2022

Winners of the Ypsomed Innovation Award 2022 announced

01/11/2023 - 11:00am Press Releases Ypsomed Group

Burgdorf - The winners of the Ypsomed Innovation Award 2022 were honoured yesterday evening at the PwC Switzerland New Year's Apéro in Bern. The winners are machineMD (1st place), Pace Locator (2nd place) and Compact Motion (3rd place). The Innovation Award, worth a total of CHF 100,000, is presented every two years by the Ypsomed Innovation Fund Foundation. The aim is to promote the transfer of knowledge and technology from universities of applied sciences and universities in the "Espace Mittelland" region.

Ypsomed and Mediq complete the sale of DiaExpert

01/03/2023 - 7:00am Press Releases Ypsomed Group

Burgdorf – Ypsomed (SIX: YPSN) and Mediq are completing the sale of DiaExpert. The transaction strengthens Ypsomed's focus on the development, manufacture and distribution of its own high-quality medical technology products for people with chronic conditions.

Eli Lilly is focusing on its successful drug portfolio and is halting its ambition to enter insulin pump business. Ypsomed remains committed to its US YpsoPump ambitions with a new partner.

12/09/2022 - 7:00am Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Eli Lilly and Company (NYSE: LLY) has decided to fully focus on its successful drug portfolio. Therefore, Lilly decided to stop the joint project with Ypsomed (SIX: YPSN) to enter the US insulin pump market in 2026. Ypsomed plans to submit its YpsoPump system to the FDA in the second half of 2023 according to plan, and subsequently commercialize the system with a new partner.

Ypsomed and CamDiab launch the first system for automated insulin dosing with Abbott’s FreeStyle Libre 3

11/25/2022 - 7:00am Press Releases Ypsomed Group

Burgdorf – Ypsomed announces that its mylife Loop is now authorized to work with Abbott’s FreeStyle Libre 3 sensor in Germany. The mylife YpsoPump and the FreeStyle Libre 3, combined with the mylife CamAPS FX algorithm from CamDiab, form an intelligent and automated insulin delivery system (AID) designed to help people with type 1 diabetes to better control their glucose levels and alleviate the burden of daily diabetes management.